Evidence map›Paper›PMID 29445555›Full record

ArticleCase reports in oncological medicine2017

Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR.

Asako Yanagisawa, Satoshi Hirano, Shinichiro Shimizu, Takuma Hiroishi, Kohei Shikano, Noriko Hayama, Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Sukeyuki Nakamura and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Asako YanagisawaDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Satoshi HiranoDepartment of Medical Oncology, Funabashi Municipal Medical Center, Chiba, Japan.ORCID 0000-0001-5392-8337
Shinichiro ShimizuDepartment of Pathology, Funabashi Municipal Medical Center, Chiba, Japan.
Takuma HiroishiDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Kohei ShikanoDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Noriko HayamaDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Tetsuo FujitaDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Hiroyuki AmanoDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Makoto NakamuraDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Sukeyuki NakamuraDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Hiroshi TabetaDepartment of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
Funabashi Municipal Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of metastatic recurrence of carcinoid tumor accompanied by carcinoid syndrome in a 68-year-old Japanese man, 12 years after resection of typical pulmonary carcinoid. Histopathologic examination from percutaneous liver biopsy revealed metastatic typical carcinoid. Clinical symptoms gradually improved after administration of octreotide LAR. Two years after starting treatment, the disease remains well controlled. This case report illustrates the possibility of antiproliferative effects of octreotide LAR on typical pulmonary carcinoid.

Identifiers

PMID29445555
PMCPMC5763055
OpenAlexW2779966973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.